VANCOUVER, BC and HALIFAX, NS, May 7, 2025 /CNW/ -- BioVaxys Technology Corp. (CNSX:BIOV.CN) (FRA:5LB) (OTC-BB:BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CNSX:SONA.CN) (OTC: SNANF) ("Sona") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on BioVaxys' DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The heat for THT is delivered to tumors using infrared light that is absorbed by Sona's proprietary biocompatible Gold Nanorod ("GNR") technology which elicits a strong immune response.
Read more at newswire.caThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/AI%20(artificial%20intelligence)/AI%20technology%20concept%20by%20NMStudio789%20via%20Shutterstock.jpg)
/Space/Planet%20earth%20with%20flying%20rocket%20by%20Sergey%20Mironov%20via%20Shutterstock.jpg)
/Sign%20of%20Intel%20at%20entrance%20%20by%20michaelmond.jpeg)